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Introduction 
Alzheimer’s disease (AD) is a 
progressive, pathological, irreversible 
disease entity of the Central Nervous 
System (CNS) (Pedrini et al. 2009). AD, 
the most common type of dementia, 
constitutes as a huge health problem and 
has a significant influence on society. 
Current estimates suggest that nowadays 
24 million people worldwide suffer from 
dementia (Pennanen et al. 2004). AD 
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ABSTRACT 
Alzheimer’s disease (AD) is a highly complex, progressive, age-related 
neurodegenerative human disease entity. The genetic basis of AD is 
strictly connected with occurrence of mutations in Amyloid Precursor 
(APP) gene on chromosome 21. Molecular mechanism that leads to AD 
development still remains unclear. Recent data reported that it is closely 
correlated with Endoplasmic Reticulum (ER) stress conditions, which 
subsequently activate Unfolded Protein Response (UPR) signaling 
pathways, via the induction of protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), as a self-protective, adaptive response to 
adverse stress conditions. That results in the attenuation of global protein 
synthesis and, on the contrary, selective translation of Activating 
Transcriptor Factor 4 (ATF4) and secretase β. Interestingly, under 
prolonged, severe ER stress UPR may switch its signal into apoptotic cell 
death. That ensues by ATF4-CHOP-mediated activation of a range of 
pro-apoptotic genes and, on the other hand, downregulation of the 
expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) 
genes. Current investigations suggest that inhibitions of PERK activity 
may contribute to the attenuation of the deposition of toxic senile plaques 
in the brain tissue and, as a result, prevent degeneration of neurons and 
decline in cognitive abilities. 
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with the highest frequency affect 
individuals in advanced age, but it is not 
a rigid rule, since AD may also affect 
younger people before the age 65 
(Guerreiro et al. 2012, Babusikova et al. 
2011). Type of AD, that tends to 
develops in individuals under 65 years is 
termed early-onset AD (EOAD), but in 
patients over 65 years is known as a late-
onset AD (LOAD) (Tang &  Gershon 
2003). Interestingly, the number of 
patients with dementia is steadily 
increasing. Estimates suggest that AD 
may affect 65.7 million of people by 
2030 and 115.4 million by 2050 
(Babusikova et al. 2011).  
AD is strictly connected with 
numerous changes not only in anatomy 
of tissue brain, but also in its 
biochemistry, genetic and function 
(Babusikova et al. 2011). The general 
features of AD are closely associated 
with memory loss and impairment of 
cognitive skills. AD and other 
neurodegenerative entities such as prion 
and Parkinson’s diseases are connected 
with the accumulation of the misfolded 
or unfolded proteins in the lumen of the 
ER, which evoke ER stress conditions. 
That elicits activation of the PERK 
kinase and, as a consequence, Unfolded 
Protein Response pathways, that 
constitutes as a pro-adaptive cellular 
program to cope with unfavourable stress 
conditions. Paradoxically, long-termed 
stress conditions and over-activation of 
the PERK-dependent signaling pathways 
switch the pro-adaptive cellular response 
to pro-apoptotic signaling pathway 
(Moreno et al. 2012). Above-mentioned 
process leads to synaptic failure and 
significant loss of brain mass in AD 
patients (Pennanen et al. 2004). The main 
cause of Alzheimer’s disease still 
remains unclear, but several lines of 
evidence suggest that the core of the 
problem lies in genetic disorder. 
Nowadays, available AD treatment is 
insufficient, since may only alleviate 
symptoms of AD. Due to that fact better 
understanding of the molecular 
mechanisms, that elicit cell death by 
apoptosis is a promising avenue on 
developing more effective AD treatments 
(Ballard et al. 2011). 
 
Gene mutations and mechanisms 
involved in Aβ plaques aggregation 
At the neuropathological level 
deposition of neurotoxic amyloid beta 
(Aβ) plaques in tissue brain as well as 
significant loss of neurons represent the 
main hallmark of AD (Kumar &  Walter 
2011). Senile plaques among the neurons 
in the brain are predominantly composed 
of Aβ peptide consisting of 39-42 amino 
acids, which is generated during Amyloid 
Precursor Protein (APP) processing. 
Longer form of Aβ consisting of 42 
amino acids creates aggregates with 
higher frequency (Kumar &  Walter 
2011), since it is inherently more 
fibrillogenic as compared to the shorter 
form of Aβ40 (Price et al. 1995). Aβ40 is 
a predominant variant, which represent 
approximately 90% of all generated 
fragments of Aβ (Decock et al. 2016). 
Numerous studies were undertaken to 
gather knowledge about the genetic basis 
of AD. APP on chromosome 21. is the 
first detected gene that is strictly 
connected with AD development (Tang 
&  Gershon 2003). The product of the 
APP gene is one of the I transmembrane 
glycoprotein, that occurs in three 
different isoforms such as: APP695, 
APP751, APP770 amino acids (Belyaev 
et al. 2010). Proteolytic cleavage of the 
product of APP gene may occur via two 
different molecular pathways: 
amyloidogenic and non-amyloidogenic. 
During the first process a vital role plays 
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secretases β and γ, but during the second 
one α and γ (Ehehalt et al. 2003). 
Secretase β, also termed Beta-secretase 1 
(BACE1), belongs to the family of 
aspartyl protease (Dislich &  
Lichtenthaler 2012) and, like APP, it is 
expressed in several areas of the brain. 
Interestingly, to confirm a fundamental 
role of BACE1 in AD pathogenesis 
scientists reported its increased level and 
enhanced activity in post mortem AD 
brains (Fukumoto et al. 2002, Harada et 
al. 2006). Furthermore, the level of 
secretase β and its biological activity are 
increased nearly twofold in AD tissue 
brain (Li et al. 2004). Secretase γ consists 
of a complex of proteins such as 
presenilin 1 (PS1) and presenilin 2 (PS2), 
nicastrin, anterior pharynx-defective 1 
(Aph1) as well as presenilin enhancer 2 
(Pen2) (Cole &  Vassar 2007). The third 
one, secretase α, is the member of the 
ADAM 10 family of disintegrin 
metalloproteinase (Lichtenthaler 2012). 
The physiological processing of APP 
occurs within the Aβ sequences, 
therefore precludes generation of full-
length Aβ (Sisodia 1992). During this 
pathway first cleavage through secretase 
α, at the specific site K687/L688, 
releases two extracellular products such 
as N- terminal APPsα and C-terminal 
fragment C83. The second one is 
processed via secretase γ that leads to the 
production of two smaller, non-
amyloidogenic fragments: p7 and p3 
(Vassar 2004). Amyloidogenic APP 
processing via secretase β occurs 
generally at the specific site such as 
M671/D672 and G680/Y681 (Vassar et 
al. 2009). That generates amino-terminal 
fragment APPsβ as well as membrane-
associated C99, that is proteolytically 
cleaved by secretase γ. After the second 
cleavage toxic Aβ peptide and amino-
terminal fragment termed APP 
intracellular domain (AICD) is generated 
(Chow et al. 2010). Secretase γ is a 
specific enzyme that cleaves C99 
fragment at sites that generates Aβ 
consisting of different number of amino 
acids such as: G708/G709 - Aβ37; 
G709/V710 – Aβ38; V711/I712 – Aβ40; 
V713/I714 - Aβ42 (Tian et al. 2010, 
Perez et al. 1999). Hence, secretase γ 
processing is fundamental for AD 
development, since it creates Aβ 
consisting of different number of amino 
acids, including its pathogenic, toxic 
form Aβ42 (Vassar et al. 2009) (Fig. 1).  
Chromosome 21. is known as the 
smallest human autosome. Mutations in 
14 known genes localized on 
chromosome 21. are known as a major 
cause of numerous monogenic disorders 
(Hattori et al. 2000). There is a body of 
evidence suggesting that APP mutations 
constitute as one of the main cause of 
EOAD as well as Familial Alzheimer’s 
disease (FAD) with autosomal dominant 
inheritance. That leads to rapid changes 
in brains’ neurons and, as a consequence, 
pathological cleavage of APP, which 
cause amyloidosis via extracellular 
deposition of Aβ plaques among the 
neurons (Weggen &  Beher 2012). 
Moreover, above-mentioned APP 
mutations lead to the aberrant cleavage of 
APP via specific secretases (Hardy 
1997). It has been reported that the most 
common APP mutations are the London, 
Dutch, Swedish and Flemish among 
others (Tang &  Gershon 2003) (Tab. 1). 
Mutations in APP gene, which are 
localized at the cleavage site especially 
for secretase β promote APP processing 
in amyloidogenic pathway, but mutations 
near the cleavage site for secretase γ 
cause increased generation of Aβ42 with 
higher ability to creation of senile 
plaques in tissue brain (Zhou et al. 2011). 
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Figure 1. Molecular mechanisms of processing of the APP by α, β and γ secretases (Aβ – amyloid beta, APP 
– Amyloid Precursor Protein, APPsα - soluble Amyloid Precursor Protein-α, APPsβ - soluble Amyloid 
Precursor Protein-β,  AICD -  Amyloid Precursor Protein intracellular domain, C83 - 83-amino-acid C-
terminal fragment, C99 – 99-amino-acid C-terminal fragment, p3 - 3 kDa product, p7 - 3 kDa product). 
Table 1. Examples of common APP mutations that promotes generation of Aβ42. 
APP Mutation Amino acid change Site of APP mutation 
Swedish Lysine > Asparagine  
Methionine >Leucine 
670 
671 
English Histidine > Arginine 677 
Tottori Aspartic acid > Asparagine 678 
Taiwanese Aspartic acid > Histidine 678 
Leuven (Italian) Glutamic acid > Lysine 682 
Flemish Alanine >Glycine 692 
Arctic Glutamic acid > Glycine 693 
Italian Glutamic acid > Lysine 693 
Dutch Glutamic acid > Glutamine 693 
Iowa Aspartic acid > Asparagine 694 
Austrian Threonine >Isoleucine 714 
Iranian Threonine > Alanine 714 
German Valine > Alanine 715 
French Valine > Methionine 715 
Florida Isoleucine > Valine 716 
Indiana Valine > Phenylalanine 717 
London Valine > Isoleucine 717 
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ER stress activates PERK-dependent 
Unfolded Protein Response signaling 
pathways 
The ER is a network of tubules and 
sacks that extend in the cell cytosol. ER 
plays a vital role in protein synthesis, 
post-translational modifications and 
protein folding. Moreover, ER provides 
proper biosynthesis of phospholipids and 
maintains calcium homeostasis 
(Rutkowski &  Kaufman 2004, Cooper 
2000). A range of stressful, pathological 
conditions have a significant influence on 
ER function. Stress stimuli include 
deprivation of nutrients, changes in redox 
homeostasis, increased level of protein 
synthesis, hypoxic conditions, viral 
infections as well as deficiency of 
calcium ions in the ER lumen (Pytel et al. 
2014). It has been reported that one 
important role of ions calcium is to 
support functioning of ER chaperones 
and maintain proper protein folding. 
Current estimates have suggested that Aβ 
peptides trigger release of calcium ions 
toward cell cytoplasm. ER lumenal 
depletion of calcium ions has a negative 
impact on chaperone activity as well as 
protein folding (Leissring et al. 2001). 
Disturbances in physiological functions 
of ER evoke ER stress, which activates 
PERK-dependent UPR signaling network 
known as a set of pro-adaptive signaling 
pathways, which the main aim is to 
restore ER homeostasis (Xu et al. 2005). 
Above-mentioned adaptive response 
involves enhanced expression of genes, 
which are responsible for proper protein 
folding within ER lumen as well as 
degradation of pathological proteins. Due 
to adverse conditions misfolded and 
unfolded proteins are accumulated within 
the ER lumen, and subsequently global 
protein synthesis is inhibited to reduce 
influx of a new, aberrant proteins into the 
ER lumen (Xu et al. 2005). Generally, 
native monomeric proteins possess α-
helix confirmation, but the characteristic 
feature of misfolded proteins is β-sheet 
confirmation. It allows to conclude that 
aggregation of aberrant proteins within 
the ER lumen is the main cause of 
neurodegenerative diseases (Doyle et al. 
2011). Paradoxically, UPR has a dual 
role, since if during prolonged stress 
conditions the pro-survival response fails 
apoptotic cell death ensues 
(Vandewynckel et al. 2013). 
Interestingly, UPR is implicated in the 
pathogenesis of numerous human disease 
entities such as neurodegenerative 
diseases, including AD, cancer and a 
range of inflammatory diseases like 
atherosclerosis, type II diabetes, renal 
disease, arthritis as well as inflammatory 
bowel disease (Brown &  Naidoo 2012, 
Tabas &  Ron 2011).  
The lumen of the ER is crowded with 
folding enzymes and chaperones such as 
immunoglobulin heavy chain-binding 
proteins (BiP), that play a major role in 
all stages of protein folding (Brown &  
Naidoo 2012). Under normal conditions 
they create a specific complex with 
inactive ER transmembrane receptor like 
PERK (Vandewynckel et al. 2013), 
which belongs to the serine/threonine 
protein kinase. During aggregation of 
misfolded and unfolded protein within 
the ER lumen BiP dissociate from 
receptors’ catalytic domains and PERK 
undergoes oligomerisation and trans-
autophosphorylation, that trigger its rapid 
activation (Harding et al. 1999, Ma &  
Hendershot 2002). Activated PERK 
subsequently phosphorylates Eukaryotic 
Initiation Factor 2 alpha (eIF2α) at Ser51 
(Doyle et al. 2011) resulting in 
significant attenuation of global protein 
translation and induction of translation of 
only selective mRNA such as secretase β, 
ATF4 and CCAAT-enhancer-binding 
protein homologous protein (CHOP), that 
may trigger cell death via apoptosis 
(Blais et al. 2004, Nishitoh 2012, Devi &  
Ohno 2014).  
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It has been reported that eIF2 consists 
of three major parts such as subunits: α, β 
and γ (Suragani et al. 2006). Translation 
initiation is strictly dependent on eIF2, 
since it possesses the ability to create a 
multiprotein complex with guanosine 
triphosphate (GTP) and initiator-
methionyl-tRNA. Subsequently, that 
complex interacts with the smaller 
ribosomal subunit termed 40S, which 
results in creation of pre-initiation 
complex 43S, that is directly responsible 
for the initiation of protein translation 
(Kimball 1999). Above-mentioned 
complex binds to mRNA and moves 
downstream toward the initiation codon 
AUG. As a consequence of correct 
codon-anticodon pairing the 48S pre-
initiation complex is formed. During that 
process energy is released, since GTP is 
hydrolyzed to GDP via GTP-ase-
activating protein eIF5 (Elsby et al. 
2011). Creation of a new ternary 
complex is closely connected with 
conversion of GDP to GTP, which is 
catalyzed by guanine nucleotide 
exchange factor eIF2β. Interestingly, 
phosphorylation at Ser51 subunit α of 
eIF2 by activated PERK, under ER stress 
conditions, triggers inhibition of global 
protein synthesis, since exchange of GDP 
to GTP is abrogated. As a result 
formation of a new ternary complex and 
subsequent protein translation is 
effectively inhibited (Krishnamoorthy et 
al. 2001). 
There is abundant evidence that the 
level of phosphorylated eIF2α is 
significantly increased in AD brain 
tissue. Besides, currently many studies 
were undertaken to confirmed increased 
level of phosphorylated eIF2α in 
transgenic AD mouse models with 
memory impairments such as 5XFAD 
and APP/PS1 KI. These studies have 
shown that aberrant activation of PERK 
kinase in AD brain may represent the 
main mediator of eIF2α phosphorylation 
at Ser51 in AD brains (Duran-Aniotz et 
al. 2014). Likewise, recent data have 
suggested that increased level of 
phosphorylated eIF2α in tissue brain of 
AD patients and APP transgenic mice is 
accompanied with higher level of 
secretase β, that is responsible for the 
activation of Aβ production (Devi &  
Ohno 2014). It has been reported that 
monomers of Aβ become toxic for brains 
nervous tissue after their aggregation into 
oligomers, and then in higher aggregated 
conformations (Lorenzo &  Yankner 
1994, Pike et al. 1991). 
 
Molecular mechanisms of ER stress-
induced apoptosis 
The crucial role of the activation of 
UPR signaling network is to rebalance 
ER homeostasis. Generally, UPR is 
known as a molecular mechanism by 
which ER copes with adverse, 
pathological conditions (Wagner &  
Moore 2011). During severe and long-
termed stress conditions pro-adaptive 
signaling pathways of the UPR are 
insufficient. Persistent activation of ER 
transmembrane receptors and CHOP may 
evoke cell death via apoptosis (Szegezdi 
et al. 2006). The characteristic hallmark 
of CHOP is its expression at low 
concentrations during physiological 
conditions, but its synthesis is 
significantly elevated under prolonged 
stress conditions. Transcription of CHOP 
occurs when ER membrane-bound 
receptors, such as PERK, are in active 
state. Notably, PERK/eIF2α/ATF4 
signaling network, induced by ER stress, 
triggers markedly elevated expression of 
CHOP, that results in apoptotic cell death 
(Oyadomari &  Mori 2004). 
There is a body of evidence 
suggesting that ER stress-induced 
apoptosis is closely associated with 
human disease entities including 
neurodegenerative diseases (Tabas &  
Ron 2011), but the mechanism 
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responsible for switching pro-adaptive 
signaling branches into pro-apoptotic still 
remains unclear (Doyle et al. 2011). High 
level of phosphorylated eIF2α, as a 
consequence of PERK activation, results 
in enhanced translation of ATF4. That 
stimulates expression of numerous genes 
responsible for adaptive response to 
adverse conditions (Schonthal 2012). On 
the contrary, during ER stress conditions, 
ATF4 as a transcription factor 
upregulates expression of pro-apoptotic 
DNA Damage Inducible Transcript 3 
(DDIT3) gene  that encodes CHOP 
protein (Dey et al. 2010). CHOP is 
involved in downregulation of the 
expression of the anti-apoptotic Bcl-2 
gene family and, adversely, upregulation 
the pro-apoptotic genes encoding 
proteins such as Bcl-2-like protein 11 
(Bim), BH3 Interacting Domain Death 
Agonist  (Bid), Phorbol-12-myristate-13-
acetate-induced protein 1 (Noxa),  p53 
upregulated modulator of apoptosis  
(Puma) among others. Above-mentioned 
proteins are the members of the BH3 
domain-only proteins and possess the 
ability to the induction of apoptosis via 
attenuation of biological activity of anti-
apoptotic Bcl-2 proteins (McCullough et 
al. 2001, Shamas-Din et al. 2011).  
Furthermore, one of the 
transcriptional target of CHOP is Growth 
arrest and DNA damage-inducible 
protein (GADD34), which may 
dephosphorylate eIF2α, thus lead to 
global translation recovery under non-
physiological, stress conditions 
(Marciniak et al. 2004). Upon this 
negative feedback loop GADD34 directly 
combine with protein phosphatase 1 
(PP1). That complex dephosphorylates 
eIF2α, triggers translational recovery, 
thus promotes ER nascent protein loads, 
ER stress and, as a result, apoptotic cell 
death (Feldman et al. 2005, Brush et al. 
2003). 
CHOP also significantly increases 
expression of ER oxidoreductin 1α 
(ERO1α) genes. Products of that genes, 
under ER stress conditions, promotes a 
hyperoxidizing environment, that evokes 
cell death via apoptosis (Sevier &  Kaiser 
2008, Simmen et al. 2010). Additionally, 
CHOP, upon oxidized conditions, may 
also activate calcium-release channel 
inositol-1,4,5-trisphosphate receptor 1 
(IP3R1). Finally, leakage of calcium ions 
into the cell cytoplasm activates calcium-
sensing kinase termed 
calcium/calmodulin-dependent protein 
kinase II (CaMKII). That events results 
in the activation of nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH 
oxidase) subunit 2 (NOX2) and 
subsequent production of reactive oxygen 
species (ROS). That creates a positive 
feedback loop, since ROS generates by 
NADPH oxidase promotes expression of 
CHOP and, as a consequence, apoptotic 
cell death (Tabas &  Ron 2011) (Fig. 2). 
 
Conclusions
Dementia constitutes one of the 
primary health problem. Current data 
suggest that approximately 24 million 
people suffer from AD and 80% cases 
involve mutations in genes. The 
characteristic feature of AD is a 
deposition of senile plaques mainly 
composed of toxic form of Aβ consisting 
of 42 amino acids, which leads to 
neuronal loss and impairment of memory 
function in AD patients. Despite, the 
molecular basis of AD is not fully 
understood, recent study has suggested 
that the core of the AD disorders lies in 
genetic factors. Mutations in APP gene 
on chromosome 21. activate 
amyloidogenic pathways, where an 
essential role, during generation of toxic 
Aβ42, plays secretase β. Moreover, 
recent data have suggested that 
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disturbances on the molecular level are 
closely associated with ER stress an 
subsequent activation of PERK-
dependent UPR signaling branches, that 
possess a dual role such as pro-adaptive 
and pro-apoptotic, which depends on the 
severity of stress conditions as well as 
exposure time of neurons to unfavorable 
factors. 
Nowadays, only symptomatic 
treatments is available for cognitive 
decline in AD. Current data suggest that 
attenuation of PERK via its small-
molecule inhibitors may prevents 
excessive phosphorylation of eIF2α, thus 
block enhanced β-amyloidogenesis 
through significant decline in APP 
cleaving in amyloidogenic pathway, what 
seems to be important in future therapies.
 
Figure 2. Mechanisms of the activation of the pro-adaptive response and CHOP-induced apoptosis under ER 
stress conditions (ER – Endoplasmic Reticulum, P – phosphate group,   BiP - immunoglobulin heavy chain-
binding proteins, PERK - protein kinase RNA-like endoplasmic reticulum kinase, eIF2α - Eukaryotic 
Initiation Factor 2 alpha, ATF4 - Activating Transcriptor Factor 4, CHOP - CCAAT-enhancer-binding 
protein homologous protein , ERO1α - ER oxidoreductin 1α, GADD34 - Growth arrest and DNA damage-
inducible protein, BIM - Bcl-2-like protein 11, Bcl-2 - protein B-cell lymphoma 2, DDIT3 - DNA Damage 
Inducible Transcript 3). 
Acknowledgements 
This work was supported by grant PRELUDIUM no. 2015/19/N/NZ3/00055 from the 
National Science Centre, Poland, grant HARMONIA no. 2013/10/M/NZ1/00280 from 
FOLIA BIOLOGICA ET OECOLOGICA 
 
 
PERK KINASE AND ALZHEIMER’S DISEASE 56 
the National Science Centre, Poland and by grant of Medical University of Lodz no. 
502-03/5-108-05/502-54-170. 
 
 
References 
Babusikova, E., Evinova, A., Jurecekova, J., 
Jesenak, M. & Dobrota, D. (2011) Alzheimer's 
Disease: Definition, Molecular and Genetic 
Factors. Advanced Understanding of 
Neurodegenerative Diseases.  InTech. 
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., 
Aarsland, D. & Jones, E. 2011. Alzheimer's 
disease. Lancet, 377(9770): 1019–1031. 
Belyaev, N. D., Kellett, K. A., Beckett, C., Makova, 
N. Z., Revett, T. J., Nalivaeva, N. N., Hooper, 
N. M. & Turner, A. J. 2010. The 
transcriptionally active amyloid precursor 
protein (APP) intracellular domain is 
preferentially produced from the 695 isoform 
of APP in a {beta}-secretase-dependent 
pathway. The Journal of biological chemistry, 
285(53): 41443–41454. 
Blais, J. D., Filipenko, V., Bi, M., Harding, H. P., 
Ron, D., Koumenis, C., Wouters, B. G. & Bell, 
J. C. 2004. Activating transcription factor 4 is 
translationally regulated by hypoxic stress. 
Molecular and cellular biology, 24(17): 7469–
7482. 
Brown, M. K. & Naidoo, N. 2012. The endoplasmic 
reticulum stress response in aging and age-
related diseases. Frontiers in physiology, 3: 
263. 
Brush, M. H., Weiser, D. C. & Shenolikar, S. 2003. 
Growth arrest and DNA damage-inducible 
protein GADD34 targets protein phosphatase 1 
alpha to the endoplasmic reticulum and 
promotes dephosphorylation of the alpha 
subunit of eukaryotic translation initiation 
factor 2. Molecular and cellular biology, 23(4): 
1292–1303. 
Chow, V. W., Mattson, M. P., Wong, P. C. & 
Gleichmann, M. 2010. An overview of APP 
processing enzymes and products. 
Neuromolecular medicine, 12(1): 1–12. 
Cole, S. L. & Vassar, R. 2007. The Alzheimer's 
disease beta-secretase enzyme, BACE1. 
Molecular neurodegeneration, 2: 22. 
Cooper, G. M. 2000. The cell: a molecular 
approach. ASM Press Sinauer Associates, 
Washington, D.C. Sunderland, Massachusetts. 
Decock, M., Stanga, S., Octave, J. N., Dewachter, 
I., Smith, S. O., Constantinescu, S. N. & 
Kienlen-Campard, P. 2016. Glycines from the 
APP GXXXG/GXXXA Transmembrane 
Motifs Promote Formation of Pathogenic Abeta 
Oligomers in Cells. Frontiers in aging 
neuroscience, 8: 107. 
Devi, L. & Ohno, M. 2014. PERK mediates 
eIF2alpha phosphorylation responsible for 
BACE1 elevation, CREB dysfunction and 
neurodegeneration in a mouse model of 
Alzheimer's disease. Neurobiology of aging, 
35(10): 2272–2281. 
Dey, S., Baird, T. D., Zhou, D., Palam, L. R., 
Spandau, D. F. & Wek, R. C. 2010. Both 
transcriptional regulation and translational 
control of ATF4 are central to the integrated 
stress response. The Journal of biological 
chemistry, 285(43): 33165–33174. 
Dislich, B. & Lichtenthaler, S. F. 2012. The 
Membrane-Bound Aspartyl Protease BACE1: 
Molecular and Functional Properties in 
Alzheimer's Disease and Beyond. Frontiers in 
physiology, 3: 8. 
Doyle, K. M., Kennedy, D., Gorman, A. M., Gupta, 
S., Healy, S. J. & Samali, A. 2011. Unfolded 
proteins and endoplasmic reticulum stress in 
neurodegenerative disorders. Journal of cellular 
and molecular medicine, 15(10): 2025–2039. 
Duran-Aniotz, C., Martinez, G. & Hetz, C. 2014. 
Memory loss in Alzheimer's disease: are the 
alterations in the UPR network involved in the 
cognitive impairment? Frontiers in aging 
neuroscience, 6: 8. 
Ehehalt, R., Keller, P., Haass, C., Thiele, C. & 
Simons, K. 2003. Amyloidogenic processing of 
the Alzheimer beta-amyloid precursor protein 
depends on lipid rafts. The Journal of cell 
biology, 160(1): 113–123. 
Elsby, R., Heiber, J. F., Reid, P., Kimball, S. R., 
Pavitt, G. D. & Barber, G. N. 2011. The alpha 
subunit of eukaryotic initiation factor 2B 
(eIF2B) is required for eIF2-mediated 
translational suppression of vesicular stomatitis 
virus. Journal of virology, 85(19): 9716–9725. 
Feldman, D. E., Chauhan, V. & Koong, A. C. 2005. 
The unfolded protein response: a novel 
component of the hypoxic stress response in 
tumors. Molecular cancer research : MCR, 
3(11): 597–605. 
Fukumoto, H., Cheung, B. S., Hyman, B. T. & 
Irizarry, M. C. 2002. Beta-secretase protein and 
activity are increased in the neocortex in 
Alzheimer disease. Archives of neurology, 
59(9): 1381–1389. 
Guerreiro, R. J., Gustafson, D. R. & Hardy, J. 2012. 
The genetic architecture of Alzheimer's 
disease: beyond APP, PSENs and APOE. 
Neurobiology of aging, 33(3): 437–456. 
Harada, H., Tamaoka, A., Ishii, K., Shoji, S., 
Kametaka, S., Kametani, F., Saito, Y. & 
Murayama, S. 2006. Beta-site APP cleaving 
enzyme 1 (BACE1) is increased in remaining 
FOLIA BIOLOGICA ET OECOLOGICA 
 
 
57  ROZPĘDEK W. ET AL. 
neurons in Alzheimer's disease brains. 
Neuroscience research, 54(1): 24–29. 
Harding, H. P., Zhang, Y. & Ron, D. 1999. Protein 
translation and folding are coupled by an 
endoplasmic-reticulum-resident kinase. Nature, 
397(6716): 271–274. 
Hardy, J. 1997. The Alzheimer family of diseases: 
many etiologies, one pathogenesis? 
Proceedings of the National Academy of 
Sciences of the United States of America, 
94(6): 2095–2097. 
Hattori, M., Fujiyama, A., Taylor, T. D., Watanabe, 
H., Yada, T., Park, H. S., Toyoda, A., Ishii, K., 
Totoki, Y., Choi, D. K., Groner, Y., Soeda, E., 
Ohki, M., Takagi, T., Sakaki, Y., Taudien, S., 
Blechschmidt, K., Polley, A., Menzel, U., 
Delabar, J., Kumpf, K., Lehmann, R., 
Patterson, D., Reichwald, K., Rump, A., 
Schillhabel, M., Schudy, A., Zimmermann, W., 
Rosenthal, A., Kudoh, J., Schibuya, K., 
Kawasaki, K., Asakawa, S., Shintani, A., 
Sasaki, T., Nagamine, K., Mitsuyama, S., 
Antonarakis, S. E., Minoshima, S., Shimizu, 
N., Nordsiek, G., Hornischer, K., Brant, P., 
Scharfe, M., Schon, O., Desario, A., Reichelt, 
J., Kauer, G., Blocker, H., Ramser, J., Beck, 
A., Klages, S., Hennig, S., Riesselmann, L., 
Dagand, E., Haaf, T., Wehrmeyer, S., Borzym, 
K., Gardiner, K., Nizetic, D., Francis, F., 
Lehrach, H., Reinhardt, R., Yaspo, M. L., 
Chromosome, m. and sequencing, c. 2000. The 
DNA sequence of human chromosome 21. 
Nature, 405(6784): 311–319. 
Kimball, S. R. 1999. Eukaryotic initiation factor 
eIF2. The international journal of biochemistry 
& cell biology, 31(1): 25–29. 
Krishnamoorthy, T., Pavitt, G. D., Zhang, F., 
Dever, T. E. & Hinnebusch, A. G. 2001. Tight 
binding of the phosphorylated alpha subunit of 
initiation factor 2 (eIF2alpha) to the regulatory 
subunits of guanine nucleotide exchange factor 
eIF2B is required for inhibition of translation 
initiation. Molecular and cellular biology, 
21(15): 5018–5030. 
Kumar, S. & Walter, J. 2011. Phosphorylation of 
amyloid beta (Abeta) peptides - a trigger for 
formation of toxic aggregates in Alzheimer's 
disease. Aging, 3(8): 803–812. 
Leissring, M. A., LaFerla, F. M., Callamaras, N. & 
Parker, I. 2001. Subcellular mechanisms of 
presenilin-mediated enhancement of calcium 
signaling. Neurobiology of disease, 8(3): 469–
478. 
Li, R., Lindholm, K., Yang, L. B., Yue, X., Citron, 
M., Yan, R., Beach, T., Sue, L., Sabbagh, M., 
Cai, H., Wong, P., Price, D. & Shen, Y. 2004. 
Amyloid beta peptide load is correlated with 
increased beta-secretase activity in sporadic 
Alzheimer's disease patients. Proceedings of 
the National Academy of Sciences of the 
United States of America, 101(10): 3632–3637. 
Lichtenthaler, S. F. 2012. Alpha-secretase cleavage 
of the amyloid precursor protein: proteolysis 
regulated by signaling pathways and protein 
trafficking. Current Alzheimer research, 9(2): 
165–177. 
Lorenzo, A. & Yankner, B. A. 1994. Beta-amyloid 
neurotoxicity requires fibril formation and is 
inhibited by congo red. Proceedings of the 
National Academy of Sciences of the United 
States of America, 91(25): 12243–12247. 
Ma, Y. & Hendershot, L. M. 2002. The mammalian 
endoplasmic reticulum as a sensor for cellular 
stress. Cell stress & chaperones, 7(2): 222–229. 
Marciniak, S. J., Yun, C. Y., Oyadomari, S., Novoa, 
I., Zhang, Y., Jungreis, R., Nagata, K., 
Harding, H. P. & Ron, D. 2004. CHOP induces 
death by promoting protein synthesis and 
oxidation in the stressed endoplasmic 
reticulum. Genes & development, 18(24): 
3066–3077. 
McCullough, K. D., Martindale, J. L., Klotz, L. O., 
Aw, T. Y. & Holbrook, N. J. 2001. Gadd153 
sensitizes cells to endoplasmic reticulum stress 
by down-regulating Bcl2 and perturbing the 
cellular redox state. Molecular and cellular 
biology, 21(4): 1249–5129. 
Moreno, J. A., Radford, H., Peretti, D., Steinert, J. 
R., Verity, N., Martin, M. G., Halliday, M., 
Morgan, J., Dinsdale, D., Ortori, C. A., Barrett, 
D. A., Tsaytler, P., Bertolotti, A., Willis, A. E., 
Bushell, M. & Mallucci, G. R. 2012. Sustained 
translational repression by eIF2alpha-P 
mediates prion neurodegeneration. Nature, 
485(7399): 507–511. 
Nishitoh, H. 2012. CHOP is a multifunctional 
transcription factor in the ER stress response. 
Journal of biochemistry, 151(3): 217–219. 
Oyadomari, S. & Mori, M. 2004. Roles of 
CHOP/GADD153 in endoplasmic reticulum 
stress. Cell death and differentiation, 11(4): 
381–389. 
Pedrini, S., Thomas, C., Brautigam, H., Schmeidler, 
J., Ho, L., Fraser, P., Westaway, D., Hyslop, P. 
S., Martins, R. N., Buxbaum, J. D., Pasinetti, 
G. M., Dickstein, D. L., Hof, P. R., Ehrlich, M. 
E. & Gandy, S. 2009. Dietary composition 
modulates brain mass and solubilizable Abeta 
levels in a mouse model of aggressive 
Alzheimer's amyloid pathology. Molecular 
neurodegeneration, 4: 40. 
Pennanen, C., Kivipelto, M., Tuomainen, S., 
Hartikainen, P., Hanninen, T., Laakso, M. P., 
Hallikainen, M., Vanhanen, M., Nissinen, A., 
Helkala, E. L., Vainio, P., Vanninen, R., 
Partanen, K. & Soininen, H. 2004. 
Hippocampus and entorhinal cortex in mild 
cognitive impairment and early AD. 
Neurobiology of aging, 25(3): 303–310. 
FOLIA BIOLOGICA ET OECOLOGICA 
 
 
PERK KINASE AND ALZHEIMER’S DISEASE 58 
Perez, R. G., Soriano, S., Hayes, J. D., Ostaszewski, 
B., Xia, W., Selkoe, D. J., Chen, X., Stokin, G. 
B. & Koo, E. H. 1999. Mutagenesis identifies 
new signals for beta-amyloid precursor protein 
endocytosis, turnover, and the generation of 
secreted fragments, including Abeta42. The 
Journal of biological chemistry, 274(27): 
18851–18856. 
Pike, C. J., Walencewicz, A. J., Glabe, C. G. & 
Cotman, C. W. 1991. In vitro aging of beta-
amyloid protein causes peptide aggregation and 
neurotoxicity. Brain research, 563(1-2): 311–
314. 
Price, D. L., Sisodia, S. S. & Gandy, S. E. 1995. 
Amyloid beta amyloidosis in Alzheimer's 
disease. Current opinion in neurology, 8(4): 
268–274. 
Pytel, D., Seyb, K., Liu, M., Ray, S. S., Concannon, 
J., Huang, M., Cuny, G. D., Diehl, J. A. & 
Glicksman, M. A. 2014. Enzymatic 
Characterization of ER Stress-Dependent 
Kinase, PERK, and Development of a High-
Throughput Assay for Identification of PERK 
Inhibitors. Journal of biomolecular screening, 
19(7): 1024–1034. 
Rutkowski, D. T. & Kaufman, R. J. 2004. A trip to 
the ER: coping with stress. Trends in cell 
biology, 14(1): 20–28. 
Schonthal, A. H. 2012. Endoplasmic reticulum 
stress: its role in disease and novel prospects 
for therapy. Scientifica, 2012: 857516. 
Sevier, C. S. & Kaiser, C. A. 2008. Ero1 and redox 
homeostasis in the endoplasmic reticulum. 
Biochimica et biophysica acta, 1783(4): 549–
556. 
Shamas-Din, A., Brahmbhatt, H., Leber, B. & 
Andrews, D. W. 2011. BH3-only proteins: 
Orchestrators of apoptosis. Biochimica et 
biophysica acta, 1813(4): 508–520. 
Simmen, T., Lynes, E. M., Gesson, K. & Thomas, 
G. 2010. Oxidative protein folding in the 
endoplasmic reticulum: tight links to the 
mitochondria-associated membrane (MAM). 
Biochimica et biophysica acta, 1798(8): 1465–
1473. 
Sisodia, S. S. 1992. Beta-amyloid precursor protein 
cleavage by a membrane-bound protease. 
Proceedings of the National Academy of 
Sciences of the United States of America, 
89(13): 6075–6079. 
Suragani, R. N., Ghosh, S., Ehtesham, N. Z. & 
Ramaiah, K. V. 2006. Expression and 
purification of the subunits of human 
translational initiation factor 2 (eIF2): 
phosphorylation of eIF2 alpha and beta. Protein 
expression and purification, 47(1): 225–233. 
Szegezdi, E., Logue, S. E., Gorman, A. M. & 
Samali, A. 2006. Mediators of endoplasmic 
reticulum stress-induced apoptosis. EMBO 
reports, 7(9): 880–885. 
Tabas, I. & Ron, D. 2011. Integrating the 
mechanisms of apoptosis induced by 
endoplasmic reticulum stress. Nature cell 
biology, 13(3): 184–190. 
Tang, Y. P. & Gershon, E. S. 2003. Genetic studies 
in Alzheimer's disease. Dialogues in clinical 
neuroscience, 5(1): 17–26. 
Tian, Y., Bassit, B., Chau, D. & Li, Y. M. 2010. An 
APP inhibitory domain containing the Flemish 
mutation residue modulates gamma-secretase 
activity for Abeta production. Nature structural 
& molecular biology, 17(2): 151–158. 
Vandewynckel, Y. P., Laukens, D., Geerts, A., 
Bogaerts, E., Paridaens, A., Verhelst, X., 
Janssens, S., Heindryckx, F. & Van 
Vlierberghe, H. 2013. The paradox of the 
unfolded protein response in cancer. 
Anticancer research, 33(11): 4683–4694. 
Vassar, R. 2004. BACE1: the beta-secretase 
enzyme in Alzheimer's disease. Journal of 
molecular neuroscience: MN, 23(1-2): 105–
114. 
Vassar, R., Kovacs, D. M., Yan, R. & Wong, P. C. 
2009. The beta-secretase enzyme BACE in 
health and Alzheimer's disease: regulation, cell 
biology, function, and therapeutic potential. 
The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 
29(41): 12787–12794. 
Wagner, M. & Moore, D. D. 2011. Endoplasmic 
reticulum stress and glucose homeostasis. 
Current opinion in clinical nutrition and 
metabolic care, 14(4): 367–373. 
Weggen, S. & Beher, D. 2012. Molecular 
consequences of amyloid precursor protein and 
presenilin mutations causing autosomal-
dominant Alzheimer's disease. Alzheimer's 
research & therapy, 4(2): 9. 
Xu, C., Bailly-Maitre, B. & Reed, J. C. 2005. 
Endoplasmic reticulum stress: cell life and 
death decisions. The Journal of clinical 
investigation, 115(10): 2656–2564. 
Zhou, L., Brouwers, N., Benilova, I., Vandersteen, 
A., Mercken, M., Van Laere, K., Van Damme, 
P., Demedts, D., Van Leuven, F., Sleegers, K., 
Broersen, K., Van Broeckhoven, C., 
Vandenberghe, R. & De Strooper, B. 2011. 
Amyloid precursor protein mutation E682K at 
the alternative beta-secretase cleavage beta'-site 
increases Abeta generation. EMBO molecular 
medicine, 3(5): 291–302. 
 
 
 
 
 
FOLIA BIOLOGICA ET OECOLOGICA 
 
 
59  ROZPĘDEK W. ET AL. 
Streszczenie 
Choroba Alzheimera (ang. Alzheimer’s disease, AD) jest przewlekłą, najczęściej 
występującą, chorobą neurodegeneracyjną prowadzącą do nieodwracalnych zmian w 
strukturze, biochemii i funkcjach mózgu. Neurodegeneracja Ośrodkowego Układu 
Nerwowego (OUN) jest wynikiem odkładania toksycznych złogów amyloidu β (Aβ) w 
tkance nerwowej mózgu. Rozwój AD jest przyczyną skomplikowanych interakcji 
między podłożem genetycznym, a czynnikami biologicznymi, które aktywują złożone 
szlaki molekularne w przebiegu schorzenia. Za jedną z głównych przyczyn uważa się 
mutacje występujące w genie kodującym Prekursorowe białko amyloidu β (ang. 
Amyloid beta Precursor Protein, APP) zlokalizowane w pobliżu cięcia białka APP 
przez wysoce specyficzne sekretazy: α, β oraz γ. Generowanie toksycznej formy Aβ o 
długości 42-óch aminokwasów, odkładanego w tkance mózgowej jako płytki starcze, 
zachodzi poprzez drogę amyloidogenną, w której uczestniczą sekretazy β oraz γ.  
Na podłożu molekularnym główną przyczyną rozwoju choroby AD jest akumulacja 
błędnie sfałdowanych lub niesfałdowanych białek w lumen Retikulum Plazmatycznego 
(ang. Endoplasmic Reticulum, ER). Skutkuje to bezpośrednim wywołaniem stresu ER, 
który prowadzi do aktywacji kinazy PERK, a następnie fosforylacji eukariotycznego 
czynnika inicjacji translacji 2 (eIF2α). W rezultacie w komórce nerwowej inhibowana 
jest translacja większości białek oraz dochodzi do preferencyjnej translacji wyłącznie 
takich białek takich jak ATF4 (ang. Activating Transcriptor 4) oraz, wyniku 
długotrwałych warunków stresowych, CHOP (ang. CCAAT-enhancer-
binding protein homologous protein).  
Nadekspresja białka CHOP prowadzi do wzmocnienia ekspresji genów kodujących: 
pro-apoptotyczne białka BH3 domain-only, GADD34 (ang. DNA damage-inducible 
protein, GADD34 oraz białko o aktywności oksydoreduktazy ER (ang. ER 
oxidoreductin 1α, ERO1α). W warunkach wysokiego stężenia białka CHOP zostaje 
osłabiona ekspresja genów kodujących anty-apoptotyczne białka Bcl-2. W rezultacie 
masa tkanki nerwowej mózgu ulega znaczącemu obniżeniu w wyniku postępującego 
procesu neurodegeneracji na drodze apoptotycznej śmierć komórkowej w przebiegu 
AD.  
 
